Rapport Therapeutics Target Price

See Rapport Therapeutics's analyst price targets ($63) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$48.69

Average Target Price

$62.80

29% upside

5 analysts in the last 4 months

High: $75 | Low: $52

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-17	Raymond JamesTiago Fauth	$75	54% upside
2026-08-12	H.C. WainwrightDouglas Tsao	$66	35.6% upside
2026-06-24	Leerink Partners	$52	6.8% upside
2026-05-21	BTIG	$65	33.5% upside
2026-05-18	Truist Financial	$56	15% upside
2026-04-10	Raymond JamesTiago Fauth	$66	35.6% upside
2026-03-09	BTIGKambiz Yazdi	$47	3.5% downside
2026-02-02	Wells FargoBenjamin Burnett	$43	11.7% downside
2025-12-19	Wells Fargo	$51	4.7% upside
2025-12-09	H.C. WainwrightDouglas Tsao	$40	17.8% downside
2025-09-16	Truist FinancialJoon Lee	$44	9.6% downside
2024-07-02	JefferiesAndrew Tsai	$35	28.1% downside
2024-07-02	Stifel NicolausPaul Matteis	$35	28.1% downside

Rapport Therapeutics (RAPP) FAQ

Rapport Therapeutics (RAPP) currently reports a target price of $63. Use the charts on this page to explore Rapport Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Rapport Therapeutics is $63, about 29.0% upside from the current share price of $48.69. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $63, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Rapport Therapeutics, and consider following RAPP for alerts when major investors trade the stock.